.jpg)
Scilex Holding Company, a renowned subsidiary of Sorrento Therapeutics, Inc., is leading the charge in the non-opioid pain management sector. This forward-thinking organization has recently announced the U.S. commercial launch of ELYXYB™, a celecoxib oral solution.
1. Scilex: A Leader in the Pain Management Industry
Scilex, a majority-owned subsidiary of Sorrento Therapeutics, Inc., is an innovative company with a strong focus on acquiring, developing, and commercializing non-opioid pain management products. These solutions are designed to treat acute and chronic pain, offering a much-needed alternative to traditional opioid treatments.
2. The U.S. Launch of ELYXYB™
Scilex's latest triumph is the commercial launch of ELYXYB™ in the United States. This groundbreaking product is now available in pharmacies, supplied through standard wholesaler and distributor channels. ELYXYB™ was given the green light by the U.S. Food and Drug Administration (FDA) on May 6, 2020, as a treatment for acute migraines in adults.
3. The Journey to Reintroducing ELYXYB™
Scilex's re-launch commercialization efforts for ELYXYB™ have been extensive. These include multiple manuscripts, a presence at the American Headache Society (AHS), and over six thousand interactions with potential customers. These efforts have laid a solid foundation for the successful re-introduction of ELYXYB™ into the outpatient marketplace.
4. Expanding Industry Leadership with ELYXYB™
The launch of ELYXYB™ marks a significant milestone for Scilex. It expands the company's presence in the pain management industry, further establishing the company as a leader in the field. ELYXYB™ is a key component in Scilex's strategy to build a comprehensive offering of novel, non-opioid treatments.
5. Redefining Pain Management Strategies
ELYXYB™ provides physicians with an additional tool in their pain management arsenal, enabling them to address migraines earlier in the patient's journey. This aligns with Scilex's ongoing mission to redefine the use of opioids as a last resort rescue medication, promoting a more patient-centric approach to pain management.
6. The Financial Potential of ELYXYB™
Apart from its therapeutic benefits, ELYXYB™ also promises to diversify Scilex's revenue stream, enhance the company's topline, and drive substantial near- and long-term accretion to its cash flows and earnings.
7. Scilex's Adept Sales Force
Scilex's sales force, composed of approximately 65 pain specialists, covers more than 80 percent of the physicians targeted for ELYXYB™. The team has been diligently executing a training and market access strategy, working closely with key customers to initiate the review process for ELYXYB™.
8. Future Plans for ELYXYB™
Looking ahead, Scilex plans to build on the FDA-approved acute migraine indication for ELYXYB™. This expansion plan includes clinical development, collaborations with key clinical leaders, and robust publication and medical education plans.
9. Scilex's Commitment to Innovation
Under the leadership of Jaisim Shah, Chief Executive Officer and President of Scilex, and Dmitri Lissin M.D., Chief Medical Officer, Scilex continues to innovate and pioneer non-opioid pain management solutions. This commitment to innovation is evident in the launch of ELYXYB™ and the company's future expansion plans.
10. Final Thoughts
In conclusion, Scilex's launch of ELYXYB™ is a significant leap forward in the realm of non-opioid pain management. It not only offers a revolutionary solution for acute migraines but also underscores Scilex's dedication to providing innovative, patient-centric treatments. As the company continues to redefine the role of opioids and pioneer non-opioid solutions, the future of pain management looks bright.